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Abstract. Compelling animal and human evidence
suggests that serotonin plays an important role in the
pathophysiology of epilepsy as it is involved in iperex-
citability, epileptogenesis, seizure generation, depression
and psychiatric disorders comorbid with epilepsy. Sero-
tonin involvement in epilepsy is complex; the reasons
are twofold i) epilepsy is in reality a spectrum disorder,
and ii) serotonin effects vary from one form of epilepsy
to another, due also to the different serotonin receptors
involved. Here, we will focus on the role of serotonin
and its 5-HT2 receptors in absence epilepsy. Our re-
cent pharmacological experimental evidence in GAERS
will be reviewed together with our preliminary opto-
genetic results. 5-HT2C receptor agonists may repres-
ent a new approach to interfere with seizure genera-
tion and seizure management. Our optogenetic exper-
iments also indicate that by modulating rhythmic cor-
tical activity, optogenetic stimulation of the serotoner-
gic system may provide seizure control without the ad-
verse effects induced by pharmacological activation of
5-HT2C receptors. Thus, targeting the serotonergic sys-
tem could provide novel insights into the pathophysiolo-
gical mechanisms of seizure generation and lead to po-
tentially novel treatments.
Keywords: Serotonin receptors, epilepsy, epileptogen-
esis, antiepileptic drugs, optogenetics, closed-loop con-
trol
1 Introduction
1.1 Serotonin systems
The dorsal raphe nucleus (DRN) and the median raphe
nucleus (MRN) of the midbrain raphe nuclei, send sero-
tonin (5-HT) widespread innervation to all brain areas
(Azmitia & Segal, 1978; van der Kooy & Hattori, 1980;
Steinbusch, Nieuwenhuys, Verhofstad & der Kooy, 1981;
Steinbusch, 1984; Van Bockstaele, Biswas & Pickel,
1993). There is some specificity regarding the two raphe
nuclei. The DRN, which is composed of approximately
50% of 5-HT neurons, is mainly responsible for the 5-HT
innervation of the mammalian medial prefrontal cortex
(mPFC) and neostriatum (Bobillier et al., 1976; Azmitia
& Segal, 1978; Jacobs & Azmitia, 1992). The MRN con-
tains fewer 5-HT cell bodies, which represent approxim-
ately 5% of the neurons in the nucleus. Although the
MRN innervates several brain regions, the projections
from this nucleus to the basal ganglia are presumed not
to release 5-HT (Soubrie, Reisine & Glowinski, 1984;
Jacobs & Azmitia, 1992). On the other hand, MRN
projections containing 5-HT innervate the hippocampus
(HIP) and septum.
The DRN contains 8,000 to 91,000 5-HT neurons in
mice and humans, respectively. It represents 30–56%
of 5-HT neurons in the Central Nervous System (CNS)
depending on the species (Jacobs & Azmitia, 1992;
Thevenot et al., 2003). It is worth noting that 5-HT
neurons may co-express and release other neurotrans-
mitters, such as glutamate, nitric oxide and GABA,
corticotropin-releasing factor (Jacobs & Azmitia, 1992;
Trudeau, 2004; Hioki et al., 2010; Lu, Simpson, Weaver
& Lin, 2010; Monti, 2010). The 5-HT neurons of the
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DRN are also heterogeneous due to the expression or
lack of some differentiation factors such as Lmx1b (Ding
et al., 2003) or pet-1 (Kiyasova et al., 2011; Gaspar &
Lillesaar, 2012; Smidt & van Hooft, 2013). Six parts
of the DRN have been described, based on their ana-
tomy and functional topography (Hale & Lowry, 2011).
Dorsal parts of the DRN send projections to the central
and basolateral nuclei of the amygdala, the dorsal hypo-
thalamic area and the mPFC (Lowry et al., 2008). The
ventral part of the DRN innervates the sensorimotor cor-
tex and the caudate putamen. The lateral part projects
mainly to subcortical regions, including the lateral hypo-
thalamus and the superior colliculus. The interfascicu-
laris part projects to the HIP and the medial septum.
The rostral parts send projections to the caudate puta-
men and the substantia nigra (SN), whilst the caudal
part sends projections to the amygdala, ventral HIP and
thalamic nuclei. The DRN also receives several afferents
from the lateral habenula, the preoptic area, the lateral
dorsal and posterior hypothalamic nuclei, basal telen-
cephalon, bed nucleus of the terminalis stria amygdala,
cingulate cortex and PFC. In central and caudal levels,
the DRN receives projections from the SN, the reticu-
late formation, the periaqueductal grey matter, and the
parabrachial nucleus (Lowry et al., 2008).
The distribution of 5-HT terminals in the brain has
been studied through autoradiography, using the bind-
ing of the two 5-HT uptake sites (serotonin transporter,
SERT) ligands [3H]-imipramine and [3H]-citalopram
(D’Amato, Largent, Snowman & Snyder, 1987; Hrdina,
Foy, Hepner & Summers, 1990; Dewar, Reader, Grondin
& Descarries, 1991), immunohistochemistry using an-
tibodies directed against SERT (Hrdina et al., 1990)
and 5-HT (Steinbusch et al., 1981; Steinbusch, 1984),
or by measuring tryptophan hydroxylase (TPH) activ-
ity (Saavedra, 1977).
The organization of 5-HT contacts on other neural
elements lacks specificity. Axon terminals of 5-HT neur-
ons are in contact with a variety of structures, including
axon terminals, dendritic spines and shafts, but rarely
neuronal somata. This organization of 5-HT varicosit-
ies and synapses in the brain lends support to the hy-
pothesis that diffusion processes or volume transmission
are the main features of 5-HT transmission (Descarries,
Seguela & Wakins, 1991; Umbriaco, Garcia, Beaulieu &
Descarries, 1995; Descarries & Mechawar, 2000).
1.2 Serotonin and Epilepsy
Compelling animal and human studies have shown 5-
HT involvement in many psychiatric and neurological
diseases, including epilepsy. It is well known that 5-
HT controls, directly or indirectly, neuron excitability
by modulating various ion channels, controlling the re-
lease of other neurotransmitters and the activation of
intracellular pathways via the activation of its pleth-
ora (fourteen) receptor subtypes (Barnes & Sharp, 1999;
D’Adamo et al., 2013). Therefore, 5-HT is logically in-
volved in the cascade of events that can change a nor-
mal neuronal network into a hyperexcitable one (Bagdy,
Kecskemeti, Riba & Jakus, 2007; Jakus & Bagdy, 2011;
Ghanbari, El Mansari & Blier, 2012). 5-HT is likely to
play a role in the initiation, propagation and mainten-
ance of seizure activity, apart from the epileptogenesis.
Here, we will focus on the evidence of a 5-HT2R con-
trol of epilepsy. 5-HT2ARs, along with 5-HT2B and 5-
HT2C, belong to the 5-HT2 subfamily that consists of
three Gq/G11-coupled receptor. 5-HT2A/2CRs in gen-
eral mediate excitatory effects of 5-HT on CNS neurons
(Di Giovanni, Di Matteo, Pierucci, Benigno & Esposito,
2006; Millan, Marin, Bockaert & la Cour, 2008).
Classically, epilepsy syndromes are classified into two
distinct types, focal and generalized, according to the
brain circuitry that sustain the oscillations that lead to
seizures, site of seizure onset, electroencephalographic
and behavioural characteristics (Berg et al., 2010). Gen-
eralized and focal epilepsy also differ in the nature of
the pathological and neurochemical imbalance between
glutamate and GABA function. Indeed, drugs that in-
crease extracellular GABA levels and/or GABA trans-
mission are first choice in focal/generalized convulsive
epilepsy, whereas they exacerbate generalized noncon-
vulsive seizures. As matter of fact, a structural GABA
analogue, gabapentin, which increases GABA synthesis,
exacerbates generalized nonconvulsive absence seizures
(ASs) and is not indicated in non-convulsive epilepsies
(Manning, Richards & Bowery, 2003). Consistently, we
have shown that an increase of tonic GABA inhibition
is a conditio sine qua non for the generation of absence
seizure in rat and mouse models of the this form of epi-
lepsy (Cope et al., 2009; Errington, Gibson, Crunelli &
Cope, 2011, 2014).
1.3 Absence Seizures
A typical AS consists of a sudden and relatively short
period of a lack of consciousness, which is invariably ac-
companied by a stereotypical EEG activity of synchron-
ous and generalized spike and wave discharges (SWDs).
ASs are present in various idiopathic generalized epilep-
sies (IGEs), while they are the only phenotype in child-
hood absence epilepsy (CAE). In CAE, the average age
in which ASs start is 3 to 8 years and they are neither
induced or generated by either visual or other sensory
stimuli. The majority (∼ 60%) of children suffering from
CAE show spontaneous remission often around adoles-
cence, although, in approximately a third of cases, ab-
sences continue later in life. This benign outcome of
CAE concords with a lack of metabolic and neuropatho-
logical signs in this epilepsy. Nevertheless, in up to 90%
of CAE sufferers for whom ASs persist during adult-
hood, there is the occurrence of generalized tonic clonic
seizures (GTCSs) (Crunelli & Leresche, 2002).
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The annual incidence rate of CAE is 2–8 per 100,000
children under 15 years of age, and its prevalence is 2–
10% among children with any type of epilepsy. CAE is
genetically determined, with a 16–45% positive family
history. Although penetrance is incomplete, a concord-
ance of 70–85% and 33% has been reported in monozy-
gotic twins and first-degree relatives, respectively. Thus,
CAE is commonly described as a familial disease with a
complex genotype, and evidence exists that it may rep-
resent a channelopathy. Indeed, the emerging picture
from the vast majority of genetic studies of AS cohorts
preferentially points to abnormalities in genes encoding
either calcium channels and/or GABA receptors, though
it needs to be stressed that in many of these studies,
ASs were not the only epileptic phenotype (Crunelli &
Leresche, 2002).
As far as the pathophysiological mechanisms of ASs
are concerned, invasive experimental work (Williams,
1953) and more recent non-invasive imaging studies in
humans (Holmes, Brown & Tucker, 2004; Hamandi et
al., 2006; Bai et al., 2010) have indicated that these
seizures are generated by paroxysmal electrical activity
of cortical and thalamic networks. In particular, stud-
ies in mouse and rat genetic absence models have shown
that SWDs initiate in somatosensory cortex, from where
they rapidly spread to other cortical areas and to the
thalamus. The presence of a cortical “initiation site” for
SWDs of ASs has now been conclusively demonstrated
in CAE and other patients with ASs, challenging the
classical view of a SWD as a fully generalized EEG par-
oxysm, at least at its onset.
The main activity of layer V/VI cortical neurons dur-
ing SWDs are rhythmic depolarizations that occur in
phase with the EEG spike, and whose waveform is
drastically different from the classical paroxysmal de-
polarizing shifts of convulsive epilepsies. Possible can-
didates for cortical abnormalities underlying the expres-
sion of this firing pattern may include an increased
NMDA-mediated excitation in deep layers, a decreased
GABAergic inhibition in layer II/III and/or abnormal-
ities in HCN channels. In NRT neurons in vivo, the en-
hanced and more synchronous cortical volley of SWDs,
together with the convergence of the corticothalamic in-
put, results in bursts of EPSPs, that at times generate
a T-type Ca2+ channel dependent high frequency burst
of action potentials in correspondence to each spike of
the SWD. Alterations in GABA-A γ2 subunits, T-type
Ca2+ channels, gap-junction coupling and/or excitat-
ory and inhibitory synaptic strengths have been sug-
gested to occur in the NRT of genetic absence models.
The strong and prolonged inhibitory output of the NRT,
coupled to the deficient GABA transporter-1, lead TC
neurons to the presence of rhythmic sequences of 4–6
GABAA IPSPs and a marked increase in tonic GABAA
inhibition. Thus, the firing rate of these thalamic neur-
ons during ASs decreases and only occasional action po-
tentials are observed in synchrony with the spike com-
ponent of SWDs. Notwithstanding, there is always a
synchronized output from thalamus to cortex during
ASs (Crunelli & Leresche, 2002).
1.4 Role of 5-HT in Generalized Epilepsy:
Pharmacological Evidence
Bonnycastle, Giarman and Paasonen (1957) proposed
the implication of 5-HT in epilepsy for the first time
in the late fifties. Successively, a large body of evid-
ence has confirmed a direct relationship between 5-HT
impairment and epilepsy, both in generalized and fo-
cal epilepsy (see Svob Strac et al., 2016). For instance,
an increase in 5-HT CNS concentration, by using 5-HT
transporter (SERT) blockers or increasing its metabol-
ism by introducing more tryptophan to the diet, has
been associated with an antiepileptic activity, while a
decrease in 5-HT brain concentration leads to a dimin-
ished threshold for various types of convulsive seizures
(see Bagdy et al., 2007). Moreover, an increase of the
firing rate of DRN neurons contextually to ASs (Lo¨rincz,
Olah, Baracskay, Szilagyi & Juhasz, 2007), a decrease in
5-HT metabolite 5-hydroxyindoleacetic acid (5-HIAA)
level in the thalamus and a significant negative correla-
tion between the severity of epilepsy (as time spent in
ASs) and the thalamic levels of 5-HT (Midzyanovskaya
et al., 2006) have been observed in WAG/Rij (Wistar
Albino Glaxo/Rijswijk) rat model of absence epilepsy.
Many anti-epileptic drugs (AEDs) also act by elevat-
ing brain extracellular 5-HT, and many SSRIs show an
antiepileptic effect (Bagdy et al., 2007). Moreover, a
common serotonin dysfunction may underlie both epi-
lepsy and comorbid depression, seen in epileptic patients
(Kanner et al., 2012; Guiard & Di Giovanni, 2015; Svob
Strac et al., 2016). There is a clear association between
the ASs and behavioural states, with clinical seizures
occurring preferentially in states of ‘decreased or fluctu-
ating vigilance’, and very few during deep stages of non-
REM sleep. This behavioral state-dependence implies
that, as it is the case for other oscillations generated by
the thalamocortical loop, the expression of SWDs is con-
trolled by various neuromodulatory systems (Steriade &
McCarley, 2005; Saper, Fuller, Pedersen, Lu & Scam-
mell, 2010). These include, among others, monoam-
inergic systems in the brainstem (Lo¨rincz & Adaman-
tidis, 2017), cholinergic systems in the basal forebrain
and brainstem (Steriade & McCarley, 2005), and sero-
toninergic system originating in the raphe nuclei. The
activity of neurons in these neuromodulatory neurons is
highly brain state-dependent (Lo¨rincz & Adamantidis,
2017) and their selective stimulation or inhibition leads
to brain state changes (Carter et al., 2010; Xu et al.,
2015; Eban-Rothschild, Rothschild, Giardino, Jones &
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de Lecea, 2016). Given the behavioural-state depend-
ence of ASs and the prominent effects of neuromodulat-
ors on brain states, external changes in the neuromodu-
lator systems could in principle affect the expression of
ASs. This novel therapeutic approach would be bene-
ficial as monotherapy with gold-standard anti-absence
drugs is only effective in 50% of CAE patients (Glauser
et al., 2010). Indeed, it has been shown that drugs that
affect the tone of the 5-HT system can modulate, and
in some cases abolish ASs when injected systemically.
Nevertheless, none of the common AEDs target the 5-
HT system, at least as main mechanism. Selective 5-HT
ligands may indeed induce dangerous off-target effects.
Therefore, the challenge for pharmaceutical research is
to develop new 5-HT compounds with better side effects
profile, potentially efficacious for both epilepsy and its
comorbid depression (see our recent review Svob Strac
et al., 2016).
Of the plethora of 5-HTRs, the 5-HT2CR seems to
be the most promising since it has been shown to be
involved in generalized convulsive epilepsy, seizure gen-
eration and network excitability (Isaac, 2005; Jakus &
Bagdy, 2011). Moreover, 5-HT2C knock down (KO)
mice show spontaneous, occasionally lethal, tonic-clonic
seizures (Tecott et al., 1995). Furthermore, in 5-HT2C
KO mice the threshold for electrical (kindling, elec-
troshock), audiogenic and chemical-induced (i.e., by
pentylenetetrazol; PTZ) seizures was decreased (Ap-
plegate & Tecott, 1998; Heisler, Chu & Tecott, 1998).
Consistently, treatments with 5-HT2CR agonists in-
creased the threshold for PTZ and electroshock-induced
seizures in mice (Upton, Stean, Middlemiss, Blackburn
& Kennett, 1998). On the other hand, 5-HT2CRs do
not seem to affect focal epilepsy. For instance, meta-
chlorophenylpiperazine, lorcaserin, but not RO60-0175,
5-HT2C agonists with different pharmacological profiles
(Fletcher & Higgins, 2011; Higgins et al., 2013), were
able to stop the hippocampal maximal dentate gyrus ac-
tivation (MDA) in a rat temporal lobe epilepsy (TLE)
model (Orban et al., 2014). m-CPP and lorcaserin anti-
epileptic effects were not blocked by SB 242084 pre-
treatment, a selective 5-HT2CR antagonist, but rather
potentiated (Orban et al., 2014). Therefore, our find-
ings suggest that 5-HT2CRs are pro-epileptic and the m-
CPP and lorcaserin activate other 5-HTRs, most likely
5-HT1ARs (Orban et al., 2013). The fact that RO60-
0175 was not effective in blocking the MDA elongation
further supports the evidence that this compound is far
from being a specific 5-HT2CR tool (Damjanoska et al.,
2003; Navailles, Lagiere, Le Moine & De Deurwaerdere,
2013; Orban et al., 2014).
On the other hand, the involvement of 5-HT2CRs in
non-convulsive generalized seizures is more compelling
compared to focal epilepsy. Hitherto, the results have
been hampered by the lack of selectivity of the 5-HT2CR
available drugs (Bagdy et al., 2007; Guiard & Di Gio-
vanni, 2015).
mCPP decreased the duration of SWDs via the ac-
tivation of 5-HT2CRs in WAG/Rij rats since its effect
was blocked by SB 242084 (Jakus et al., 2003). On the
other hand, 5-HT2CRs seem not to play a role in basal
modulation of ASs (Jakus et al., 2003; Jakus & Bagdy,
2011). Similarly, DOI, a 5-HT2A/2C mixed agonist and
the two 5-HT reuptake inhibitors fluoxetine and clomi-
pramine, reduced the time spent in seizure in groggy
model of ASs (Tokuda et al., 2007). DOI-elicited de-
crease in ASs was blocked by ritanserin, a non-selective
5-HT2 antagonist, which had no effect on its own (Ohno
et al., 2010), further confirming that phasic 5-HT activ-
ation of 5-HT2Rs does not modulate the occurrence of
SWDs. Moreover, mCPP had no effect in modulating
absence seizures, while DOI reduced the total time spent
in seizure in the AY-9944 model of atypical AS (Bercov-
ici, Cortez, Wang & Snead, 2006).
We have recently investigated the effects of pharmaco-
logical manipulation of 5-HT2Rs in the expression of ab-
sence seizures of in GAERS (Genetic Absence Epilepsy
Rat from Strasbourg), another polygenic model of ASs
using selective 5-HT2C drugs (Venzi et al., 2016). Since
early results obtained with unselective 5-HTR ligands
(Marescaux, Vergnes & Depaulis, 1992b, 1992a) (see
Danober, Deransart, Depaulis, Vergnes & Marescaux,
1998) did not show any significant 5-HT modulation
of AS in GAERS, we used lorcaserin and CP809, 101,
the most selective 5-HT2C agonist available (Siuciak
et al., 2007) and the selective 5-HT2C antagonist SB
242084. 5-HT2CRs activation reduced total time spent
in seizures in GAERS. Moreover, we observed an overex-
pression of 5-HT2CRs in the ventrobasal (VB) thalamus
in GAERS compared to non-epileptic control (NEC)
rats (unpublished observations). Therefore, a dysfunc-
tion of 5-HT2CRs might be involved in the pathogenesis
of ASs and selective agonists at these receptors may be
potential targets for new anti-absence drugs.
5-HT2CRs are widely expressed in the CNS, includ-
ing key areas involved in the pathogenesis of the ASs,
such as the cortex and thalamus (Crunelli & Leresche,
2002) or areas known to modulate SWDs i.e., striatum,
nucleus accumbens and substantia nigra pars reticulata
(Depaulis, David & Charpier, 2016). Therefore, since we
administered the drugs intraperitoneally, it is difficult to
rule out which brain area is involved in the anti-absence
effect of 5-HT2CR agonists.
5-HT2CRs are expressed in thalamocortical (TC)
neurons in the dorsal lateral geniculate nucleus (dLGN)
(Coulon et al., 2010). GABAergic interneurons of the
dLGN contain 5-HT2CR mRNA, and their activation
induces an increase of phasic GABAAR inhibition in
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dLGN TC neurons in mice (Munsch, Freichel, Flockerzi
& Pape, 2003). The intracellular pathways that couple
the 5-HT2Rs to the Ca
2+-influx mechanism depend on
the PLC system and the transient receptor potential
(TRP) protein TRPC4 (Munsch et al., 2003). We in-
stead showed that mCPP (ineffective in mice; Munsch
et al., 2003) decreased phasic inhibition as well as tonic
GABAAR current in dLGN neurons in rats, an effect
blocked by pretreatment with SB 242084 (Crunelli & Di
Giovanni, 2015). 5-HT2CR GABAergic modulation is
not limited to the dLGN but is also present at the level
of the somatosensory VB thalamus, where RO 60-0175
decreased both tonic and phasic inhibition GABAA (un-
published observations). The control of tonic inhibition
seems to be phasic in nature, since SB 242084 did not
have any effects on its own, but blocked RO 60-0175
effect in wistar rats. RO 60-0175 produces a normaliza-
tion of the increased GABAA tonic current in GAERS,
thought to be a necessary mechanism for the develop-
ment of ASs (Cope et al., 2009).
5-HT in the thalamus induces depolarization of TC
neurons and change in their firing pattern from burst to
single spike activity (McCormick, 1992). 5-HT induces
membrane depolarization by inhibition of a leak K+ con-
ductance (Meuth et al., 2006) and hyperpolarization-
activated non-selective cation current (Ih) (Pape & Mc-
Cormick, 1989; Chapin & Andrade, 2001). 5-HT2CR
agonist CP809,101 and 5-HT produce similar depolar-
ization effects activating Gq protein-coupled receptors
(Coulon et al., 2010). Ketanserin, a 5-HT2A/2CR ant-
agonist, was capable of blocking 5-HT-induced switch
in the NRT neuronal pattern activity. Therefore, 5-HT
modulation of sleep-waking activity might depend on
GABAergic neurons of the NRT (McCormick & Pape,
1990; McCormick & Wang, 1991).
5-HT promotes waking and suppress REM sleep but
on the other hand 5-HT2CR KO mice have an in-
crease of waking and a reduction in NREM sleep. Dif-
ferent results come from pharmacological experiments
where selective 5-HT2CR antagonists and nonselective
5-HT2A/2CR antagonists increase SWS (slow wave sleep)
and reducing REM sleep respectively (Popa et al., 2005).
On the other hand, nonselective 5-HT2A/2CR agonists
and selective 5-HT2CR agonists increased waking and
reduced SWS and REM sleep.
During ictal activity recorded in animal models of ab-
sence epilepsy, TC neurons are generally silent (Pinault
et al., 1998; Polack et al., 2007) due to an increased cor-
ticothalamic excitatory inputs into NRT neurons com-
pared to TC neurons. We hypothesize that during ASs,
5-HT2CR agonists have antiabsence effects by decreasing
GABA release form NRT neurons into VB TC neurons
leading to a reduced GABAA phasic and tonic current.
Nevertheless, that it is not impossible that 5-HT2CRs
have both anti- and pro-epileptic effects, depending
which brain area receptor population is activated. For
example in the cortex, 5-HT2CRs are both highly ex-
pressed on inhibitory interneurons (S. Liu, Bubar, Lan-
franco, Hillman & Cunningham, 2007) and pyramidal
cortical neurons and 5-HT2CR activation can induce
increase of thalamic glutamate release (Puig, Celada,
Diaz-Mataix & Artigas, 2003).
Another potential way by which 5-HT2CRs modulate
ASs may be through other neurotransmitters such as
dopamine, and noradrenaline known to modulate the
arousal state and affecting thalamic and cortical patho-
logical oscillations seen in absence epilepsy (Di Gio-
vanni, Di Matteo & Esposito, 2008, 2010; Di Giovanni,
2013).
1.5 Therapeutic Potential of 5-HT2C Drugs in
Epilepsy
5-HT modulates normal and pathological brain excitab-
ility via the plethora of 5-HTRs. The complexity of this
control it might be due to the opposing effects of dif-
ferent receptors and the different 5-HT modulation of
the different brain areas involved in the various types
of epilepsy. 5-HT2CRs modulate generalized convulsive
tonic-clonic and non-convulsive epilepsy. On the other
hand, 5-HT2CRs do not seem to be involved in focal
epilepsy.
Our findings with 5-HT2CR agonists are promising
and suggest a therapeutic potential of these drugs for
the treatment of human generalized convulsive and non-
convulsive epilepsy. Since lorcaserin has received FDA
approval for treatment of obesity it will be easy to con-
duct a well-controlled studies to demonstrate its efficacy
in epilepsy.
One of the negative side effects of 5-HT2CR agonists
may be their potential anxiogenic effects. As a result,
new AEDs based on 5-HT2CR agonism should be lack-
ing of this and other 5-HT2CR aversive off-target effects.
Ideally optogenetic treatment of ASs would be devoided
of all the typical synthetic 5-HT ligands side effects. Our
on-going work using optogenetics to stop ASs will also
clarify the role of 5-HT in this type of epilepsy. Increas-
ing our understanding of the role of 5-HT might reveal
novel mechanisms of potential translational significance.
1.6 Role of 5-HT in Generalized Epilepsy: Op-
togenetic Evidence
Optogenetic Studies of the Serotonergic System
The activity of raphe nuclei neurons is tightly correlated
with changes in brain state changes (Urbain, Creamer
& Debonnel, 2006). While correlating neuronal activity
with specific behavioural events is essential for elucid-
ating the neuronal mechanisms underlying a variety of
brain functions, establishing causal relationships require
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tools to directly interact with neuronal populations to
boost or silence their activity and monitor the effects on
various physiological and/or behavioural functions. The
classical tools to reach these aims were to either electric-
ally stimulate various nuclei or to systemically or locally
interact with groups of neurons using pharmacological
tools. Electrical stimulation acts by directly triggering
action potentials in neurons or axons in the proximity of
the stimulating electrode. Because most nuclei consist of
populations of neurochemically heterogeneous neurons
(see Introduction) and fibers of passage, this technique
lacks specificity in terms of selectively influencing the
electrical activity of various neurochemically heterogen-
eous elements of the network albeit and its great tem-
poral specificity. On the other hand, as we showed in the
first part of this review pharmacological tools, can be re-
latively specific, but lack both temporal specificity and
when agonists are being used these can reach receptors
outside the area of action of axon terminals from which
they are released. Recent progress in genetic engineering
offers new opportunities to directly control specific neur-
onal populations. Two light-sensitive proteins, namely
Channelrhodopsin-2 (ChR2) and Halorhodopsin (Halo)
can now be used to optically activate or silence spe-
cific neuronal subtypes (Zhang, Wang, Boyden & Deis-
seroth, 2006, 2008). The use of these proteins presents
compelling advantages: 1) their expression can be tar-
geted to specific cell types and/or subcellular compart-
ments; 2) ChR2 can drive action potential firing with
millisecond precision in response to light pulses. An-
imals expressing ChR2 and/or Halo have already been
produced (Gradinaru, Mogri, Thompson, Henderson &
Deisseroth, 2009), and optical interfaces for delivering
the light to specific brain regions in behaving rodents
have been designed (Aravanis et al., 2007). It has been
recently shown that when used in combination with elec-
trophysiological recordings, optogenetic techniques can
be used to distinguish between action potentials of dif-
ferent classes of neocortical neurons by selectively trig-
gering light evoked action potentials in only one type of
cells, a method termed photostimulation-assisted identi-
fication of neuronal populations (Lima, Hromadka, Zna-
menskiy & Zador, 2009). These recently developed op-
togenetic tools have several advantages over classical
techniques: can be targeted to specific neuronal pop-
ulations, have millisecond temporal precision and can
be used to both stimulate and inhibit neuronal activity.
Selectively stimulating raphe nuclei 5-HT neurons us-
ing optogenetioc tools has been shown to profoundly
affect the spontaneous activity of a large proportion
of neurons in the primary olfactory cortex (Lottem,
Lo¨rincz & Mainen, 2016). Specifically, the baseline
activity of most neurons in the olfactory cortex is re-
duced in a rapid and transient manner, most neurons
being affected by 5-HT photostimulation in less than
100 ms. Optogenetic stimulation of raphe nuclei neurons
has been shown to suppress hippocampal ripple activity
and inhibition of these neurons increased ripple activity
(Wang et al., 2015). Thus, changes in the 5-HT con-
centration throughout the forebrain can also powerfully
influence rhythmic cortical activity.
Optogenetic targeting of various neuromodulatory
systems in vivo could lead to altered seizure dynam-
ics, the effects being mediated by local and global neur-
omodulatory actions in the brain causing changes in
network dynamics. Given the prominent effect of sero-
tonergic stimulation on cortical activity, the effect on
SWDs in animal models would be expected to be dra-
matic. This could be beneficial for two reasons. First, by
changing 5-HTneuromodulatory tone, both globally (us-
ing somatic 5-HT neuron photostimulation in the raphe
nuclei) and locally (photostimulating ChR2 expressing
5-HT fibers in various cortical and thalamic regions)
one could gain new insights in the cellular and net-
work mechanisms involved in the generation of SWDs.
This is crucial information for developing more targeted
medications. Second, since the effect of 5-HT is rapid
(< 100 ms; Lottem et al., 2016), this method could
in theory be used for closed-loop seizure detection and
ablation. Indeed, although the dominant frequency of
SWDs in various animal models is 2-3 times higher than
in humans, SWDs could be stopped after only one cycle
(the interval between individual spikes of an SWD is
> 100 ms) if proper spike detection is used. We are
using a closed loop system (Berenyi, Belluscio, Mao &
Buzsaki, 2012) in which the first spike of an SWD is used
to trigger a series of light flashes delivered from a laser
connected to an optic fiber situated in close proximity
of ChR2 expressing serotonergic neurons. This way, this
simple closed loop system quickly interacts with the gen-
erating networks and blocks the seizure before its full
blown manifestation. ChR2 can readily be expressed
in DRN 5-HT neurons (Dugue et al., 2014; Lottem et
al., 2016) and photostimulation, using very low light in-
tensity, reliably evokes action potentials in serotonergic
neurons with millisecond precision (Dugue et al., 2014)
and our preliminary data (Fig. 1). 5-HT thus has the
potential to alter ensemble activity in cortical and/or
thalamic networks. Our preliminary data confirm the
ability to powerfully affect neocortical neuronal activ-
ity as reflected in the suppression of individual neuron
firing (Fig. 2).
The activity of unidentified DRN neurons (Lo¨rincz et
al., 2007) and identified DRN 5-HT neurons (Zhan et
al., 2016) has been shown to be affected during seizures
of various types, including SWDs. It has long been
thought that, as a neuromodulator, 5-HT can have a
sustained influence on its targets without temporal mod-
10.7423/XJENZA.2017.1.01 www.xjenza.org
Targeting the Serotonin (5-HT) System to Control Seizures 9
Figure 1: EYFP-ChR2 expression in the DRN of a Tph2-ChR2(H134R)-EYFP mouse (Zhao et al., 2011). (A) Low
magnification epifluorescent image of a coronal brainstem section. The boxed area is shown in B. Aq: aqueduct.
Figure 2: DRN 5-HT photostimulation results in a prominent suppression of neocortical baseline activity. (A) (Top)
Example recording of the electrical activity of a neocortical neuron recorded in the motor cortex of an anesthetized mouse. 5-HT
photostimulation (indicated by the horizontal blue bar) results in a rapid and prominent suppression of action potential firing. The
inset shows the superimposed spikes, red trace is the averaged spike waveform. The blue bar marks the 5-HT photostimulation (train
of 10 ms pulses at 10 Hz). (Bottom) Firing rate of the recorded neuron. (B) Peri stimulus time histogram of the neuron illustrated in
(A). The photostimulation is illustrated by the blue bar. (C) Scatter plot comparing firing rates under control and photostimulated
conditions for 9 recorded neurons. A linear regression fit is superimposed.
ulation. Interestingly, recently it has been shown, that
the firing of some DRN neurons is also modulated at
a faster timescale and can be phase-locked to specific
behavioural events. Specifically, a subset of identified
serotonergic neurons show phasic activation to reward
predicting cues (Cohen, Amoroso & Uchida, 2015) and
encode reward (Z. Liu et al., 2014), suggesting the im-
portance of serotonergic system in guiding behaviour.
Given the transient activation of DRN 5-HT neurons
linked to specific behavioural effects and the ability of
the 5-HT system to rapidly influence cortical electrical
activity, the serotonergic system appears as an attract-
ive neuromodulatory candidate to control pathological
synchronous cortical electrical activity on a rapid times-
cale.
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2 Conclusion
The findings reviewed here highlight an important role
for 5-HT and its receptors, especially the 5-HT2CRs,
in both pathologic neuronal excitability in epilepsy and
comorbid affective disorders. The available literature
suggests that antagonism at 5-HT2CRs might have be-
neficial effects on TLE patients, while their activa-
tion shows a clear anti-absence effect. These paradox-
ical anticonvulsant efficacy of 5-HT2CR antagonists and
agonists can be reconciled, taking into consideration
that i) the two types of epilepsy have a different net-
work substrate, ii) both agonism and antagonism induce
5-HT2CR desensitization or downregulation (Graybiel,
2004), and/or iii) the existence of different populations
of 5-HT2CRs with different signal transduction mechan-
isms. Moreover, the anti- versus pro-epileptic effects of
the 5-HT2CR activation might depend on the dose of the
ligands used, with a pro-convulsive effects being present
when the receptors are excessively activated.
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